GHRL and obesity due to melanocortin 4 receptor deficiency: The limited efficacy of targeting ghrelin signaling in obesity has also been confirmed in humans: a randomized clinical trial with an anti-ghrelin vaccine demonstrated no additional weight loss compared to placebo, despite a clear induction of anti-ghrelin antibodies [270].